Wide Open Agriculture Limited Overview
Wide Open Agriculture is a Perth-based, ASX-listed ingredient technology company that is trying to turn the Australian sweet lupin, a legume that Western Australia grows in large quantities but which is mostly used as stock feed, into a high-value food, beverage, cosmetic and nutraceutical ingredient. Its core asset is intellectual property: an exclusive global licence from Curtin University over a lupin protein modification process, patents and know-how acquired from Germany's Prolupin, and newer filings such as a lupin protein milk formulation. Having exited its Dirty Clean Food consumer business in 2024 and shut its owner-operated German plant in 2026, WOA is now a capital-light IP owner seeking contract manufacturers in Asia. It also aims to monetise the whole seed through protein isolate, oil and fibre. Revenue remains sub-A$1 million, cash was A$1.27 million at 30 June 2026, and the company's survival depends on converting a customer pipeline and securing low-cost manufacturing.
What the company does today
WOA develops, specifies and sells lupin-derived ingredients to business customers. Data aggregators drawing on the company's descriptions summarise the current offer as lupin protein isolates, lupin oil and fibre, and gamma conglutin. These are sold to food manufacturers, ingredient distributors and other business customers through B2B ingredient sales and tolling production services. The geographic markets cited are Australia, Europe, North America, South America and Asia (StockAnalysis / Simply Wall St company descriptions, 2026).
Market Index carries the company's current self-description. It positions WOA as a listed ingredient company pioneering lupin-based products for the food, beverage, cosmetics and nutraceutical sectors. It claims proprietary IP across the production process and a portfolio of lupin proteins, fibres, oil and other compounds intended to improve product functionality and performance.
Company's own description (FY2026 Appendix 4E, paraphrased)
The FY2026 review describes the year as a strategic transition. The company says it appointed a commercially experienced CEO and Chair, advanced commercialisation of its proprietary lupin ingredient technologies, strengthened customer and distribution relationships, expanded its IP and progressed a "whole-of-seed" product model. A detailed review of manufacturing economics led to a decision to move from owner-operated manufacturing to an asset-light contract manufacturing model, while retaining the technology, IP and commercial relationships. Management states its objective as becoming a globally relevant supplier of differentiated, high-performance lupin-based ingredients through a capital-efficient operating model.
Business model and revenue model
| Revenue stream | Status (FY2026) | Nature | Comment |
|---|---|---|---|
| Lupin protein isolate sales (B2B) | Moderated; production in Germany reduced and then halted | Product | 8 customers and more than 30 commercial launches secured by the end of FY2026 (FY2026 Appendix 4E). Supply to existing customers must be re-established via contract manufacturing |
| Third-party toll manufacturing | Completed; ended with German wind-down | Service | Pea protein contract production for a non-competitive customer; A$230k of toll income in the December 2025 quarter alone. This was the main revenue driver in FY2026 and sits in discontinued operations |
| Lupin oil | Initial small sale (cosmetics) | Product | First commercial sale to a European cosmetics company in the December 2025 quarter; hypoallergenic testing announced 30 July 2026 |
| Lupin fibre | Development / characterisation | Product (future) | Company declared a fibre product commercially ready in an earlier announcement; testing supporting commercial potential announced 6 August 2026 |
| Technology licensing / royalties | Not yet a revenue stream | Licensing (inbound) | WOA pays Curtin University a flat 3.5% royalty on net sales (revised May 2026). It does not currently earn licensing income |
| Grants and R&D tax incentive | Material "other income" | Non-operating | Other income of A$2.60M in FY2026 (continuing), including A$2.26M of R&D tax incentive refunds for FY2024 and FY2025 and A$0.29M of grant income |
Independent characterisation: WOA is best described as a pre-commercial ingredient technology company with a residual operating history. Statutory revenue (A$0.83M in FY2026 including discontinued operations) is dwarfed by its cost base, and in FY2026 the R&D tax incentive and grants exceeded revenue by roughly three times. The mix today is product (protein, oil) plus a now-ceased service line (tolling). There is no subscription revenue, and licensing is inbound rather than outbound. The intended future model resembles an "IP-owning brand manufacturer": WOA retains formulations, process know-how, product specifications and customer relationships, while contract manufacturing organisations (CMOs) in Asia carry the capital-intensive processing. In the long term, management is studying a 10,000 tonne-per-annum (tpa) owned facility in Western Australia (estimated capex about A$311M, unfunded).
Value chain position
| Value chain stage | WOA role (2026) |
|---|---|
| Lupin farming (WA Wheatbelt) | Sources seed from growers; no longer farms at scale (regenerative farming heritage via Wide Open Land Pty Ltd) |
| Primary processing (dehulling, milling, de-oiling) | Outsourced / to be outsourced to CMOs |
| Protein extraction, fractionation, drying | Proprietary process IP (Curtin licence, Prolupin patents); execution to move to CMOs |
| Ingredient specification and application development | Core in-house capability |
| B2B sales and distribution | Direct sales plus distributors (Univar Solutions China; Proeon Foods with conditional India distribution rights) |
| Consumer brand | Exited (Dirty Clean Food sold April 2024) |
Customer types and end-markets
Customer types disclosed are ingredient distributors, food manufacturers and consumer brands seeking novel plant proteins (FY2025 Appendix 4E). In addition, a European cosmetics company bought lupin oil, and pea protein toll customers were served in Germany. End-markets targeted include plant-based dairy alternatives (lupin milk, barista and beverage applications), sports and medical nutrition beverages (Univar China rollout in beverage and nutrition), bakery and other foods, cosmetics and personal care (lupin oil), and dietary fibre (lupin fibre).
Strategy
Stated strategy: "Building Better Economics" (announced 2 Jul 2026; restated in FY2026 Appendix 4E)
| Stage | Theme | Specific actions | Status (Oct 2026) |
|---|---|---|---|
| Stage 1 | Wind down owner-operated manufacturing | Orderly wind-down of the German plant; remove fixed cost and capital burden | Underway; WOAG in administration |
| Stage 2 | Transition to contract manufacturing | Capital-light CMO model for lupin protein isolate; target about 500–1,000 tpa scaled to demand; Asia preferred; retain IP, specifications and customer relationships | Four non-binding framework agreements signed (Proeon, VLS, OMN9, Haldin); about 95 CMOs screened; 12+ NDAs; definitive agreement targeted within calendar 2026 |
| Stage 3 | Build value from the whole lupin seed | Commercialise protein as the core; develop lupin oil and fibre; increase value recovered per tonne; improve sustainability credentials and gross margin | Lupin oil: first sale plus hypoallergenic testing. Fibre: testing supports commercial potential |
| Stage 4 | Plan for large-scale industrial production | Complete PFS/study for a 10,000+ tpa WA facility; invest only with demonstrated demand, unit economics, funding, regulatory and board approval | Study released 6 Oct 2026 (capex about A$311M ±30%); DFS planned for 2027; FID targeted mid-2028; first production 2031 at the earliest |
Strategic initiatives in the last 24 months
| Initiative | Date | Description |
|---|---|---|
| Univar Solutions China rollout | Sep 2025 quarter | Launch of WOA lupin protein in China's beverage and nutrition sectors; later constrained by manufacturing cost |
| Lupin Sustainability Study | Sep 2025 quarter | Independently reviewed study of lupin farming and WOA isolate; concluded lupins can contribute materially to GHG reductions |
| WA facility PFS | Commenced Sep 2025 quarter | Evolved into the Industrial Scale Manufacturing Study (Oct 2026) |
| Lupin protein milk formulation | 22 Oct 2025 | New patent filing for beverage applications |
| China market entry (CIIE) | Nov 2025 | Joined the Australian delegation to the China International Import Expo |
| Lupin oil commercialisation | Dec 2025 quarter onward | First sale to European cosmetics; hypoallergenic test results (30 Jul 2026); skin care potential claims (Oct 2026) |
| Leadership renewal | Mar–May 2026 | New CEO (Swan) and Chair (Brown) |
| Curtin royalty restructure | 25 May 2026 | Flat 3.5% royalty replaces a tiered structure |
| Contract manufacturing transition | Jul–Sep 2026 | Four framework agreements across India, Vietnam and Indonesia |
| Cost programme | Jul 2026 onward | German wind-down; deferral of board and executive fees; reduced marketing and R&D spend |
| Alternative processing technology trials | June 2026 quarter | Production trial of lupin protein isolate using an alternative processing technology; technical work on de-oiling, fractionation, purification and drying |
Medium-term targets and guidance
| Target | Detail |
|---|---|
| CMO production volume | About 500–1,000 tpa of lupin protein isolate |
| CMO partner | Execute a definitive contract manufacturing partnership within calendar 2026 |
| Industrial facility | DFS 2027; FID mid-2028; about 30 months of construction; first production 2031 at the earliest |
| Financial guidance | None provided. No revenue, margin or profitability targets |
Products & Services
Current portfolio (lupin ingredients)
| Product / brand | Description | Key capabilities (as disclosed) | Target customer | Launch / status | Pricing |
|---|---|---|---|---|---|
| Buntine Protein® (lupin protein; also marketed as lupin protein isolate) | Flagship plant protein from Australian sweet lupin using a Curtin University-developed modification process | The technology unfolds the lupin protein to improve its ability to gel, thicken and blend, which addresses lupin's historic taste, texture and gelling limitations (Market Index news, 2022). Positioned for plant-based dairy, meats, baked goods and health foods; patent-protected globally | Food and beverage manufacturers, ingredient distributors | Pilot production in WA in 2022; commercial isolate from Germany from 2024; production moderated in FY2026 and halted in July 2026 | — |
| Lupin protein isolate (Prolupin-derived process) | Isolate produced at the Grimmen plant using patents that originated at the Fraunhofer Institute (acquired by Prolupin in 2010) | Strong position in plant-based dairy applications; regulatory approvals obtained in Europe | European dairy-alternative and nutrition brands | Acquired April 2024; production wound down from July 2026 | — |
| Luve (trademark) | Prolupin's consumer-facing lupin brand, previously sold in European retail | Trademark acquired with Prolupin assets | European consumers / brand licensees | Acquired 2024; current commercial use not disclosed | — |
| Lupin protein milk formulation | Proprietary lupin protein milk for beverage applications | Patent application filed in FY2026 | Dairy-alternative and beverage brands | Announced 22 October 2025 | — |
| Lupin oil | Oil co-product from de-oiling lupin seed | Independent testing reported it as hypoallergenic (30 July 2026); company claims skin care potential | Cosmetics and personal care | First commercial sale to a European cosmetics firm in the Dec 2025 quarter | — |
| Lupin fibre | Dietary fibre co-product from protein extraction | Declared commercial-ready in an earlier announcement; testing supporting commercial potential (6 August 2026) | Food manufacturers (fibre fortification, bakery) | Development / characterisation | — |
| Gamma conglutin | Bioactive lupin protein fraction | Listed in aggregator descriptions of WOA's offer; specific claims not disclosed in sources reviewed | Nutraceuticals | Status not disclosed | — |
| Toll manufacturing services | Contract processing of third-party proteins (pea) at Grimmen | Helped recover overheads during start-up | Non-competing protein brand | FY2025–FY2026; completed in the June 2026 quarter | — |
Planned industrial-scale product slate (6 Oct 2026 study)
| Product | Modelled annual output at nameplate (tonnes) |
|---|---|
| Lupin protein isolate | 10,000 |
| Dried lupin fibre | 17,500 |
| Filtered lupin oil | 730 |
| Lupin hulls | 11,900 |
Source: Industrial Scale Manufacturing Study, as reported by Kalkine on 6 October 2026. The company states that modelled revenue of A$240–295M a year at full capacity is not a forecast and that volumes are uncontracted.
Divested / discontinued portfolio (historical)
| Product / brand | Description | Period | Disposition |
|---|---|---|---|
| Dirty Clean Food (DCF) | "Soil-to-table" regenerative food brand: beef, lamb, poultry, seafood, eggs, bakery items, fruit and vegetables, pantry staples, ready meals (pizza, cheeseboards); online retail, food service and independent supermarkets in WA | 2019–Apr 2024 | Sold to DCF Global Pty Ltd (Jay Albany) for A$1.5M |
| Dirty Clean Food Oat Milk / OatUP | Oat milk positioned as carbon-neutral; barista and retail formats; exported via distributors (DKSH Taiwan, GrowHub) | 2021–2024 | Transferred with DCF |
| Oat-milk ice cream | Vegan ice cream sold through Perth independent retailers | 2021–2024 | Transferred with DCF |
| Buntine Protein high-protein oat milk and snacks | DCF products featuring WOA lupin protein | 2022–2024 | Transferred with DCF |
Financial Narrative
Basis of preparation: Australian Accounting Standards / IFRS. FY2023 and FY2024 figures are from the FY2024 Appendix 4E. FY2025 and FY2026 figures are from the FY2026 Appendix 4E (FY2025 restated). FY2022 figures are partly from secondary sources and are flagged accordingly. FY2026 figures are unaudited.
Income statement
Notes:
-
FY2022 revenue (about A$9.3M) is from SmallCaps' coverage of the FY2022 results.
-
FY2024 net loss: A$12.74M per the preliminary (unaudited) report; the FY2025 report shows the FY2024 comparative as A$13.25M. FY2025 net loss: A$7.09M per the FY2025 preliminary report; restated to A$6.89M in the FY2026 report.
-
FY2024 EPS of -7.40c is derived as -3.17c (continuing) plus -4.23c (discontinued).
-
EBITDA is derived as pre-tax loss plus depreciation, amortisation and finance costs. FY2025 and FY2026 EBITDA are on a continuing-operations basis only. FY2026 continuing EBITDA is flattered by A$2.26M of R&D tax refunds covering two years.
-
FY2024 includes A$1.20M of impairment of fixed assets and a A$1.36M loss on sale of business. FY2025 continuing includes A$0.54M of impairment of plant and equipment.
Margins and growth (%)
Derived. FY2025 EBITDA and net margins use continuing EBITDA over continuing revenue, and group net loss over as-reported revenue (A$0.469M), respectively. FY2026 EBITDA margin uses continuing EBITDA over continuing revenue; net margin uses group loss over group revenue including discontinued operations.
Revenue CAGR FY2022–FY2026 (as reported): approximately -45% per year (A$9.3M to A$0.83M, derived). This figure reflects the deliberate exit from consumer food rather than organic decline. On a lupin-protein-only basis, revenue rose from A$0.07M (FY2024) to A$0.47M (FY2025) and A$0.83M (FY2026), but the FY2026 figure was mostly toll processing of pea protein.
Balance sheet
Notes:
-
FY2022 cash and equity are taken from the FY2023 opening balances in the FY2024 Appendix 4E. SmallCaps reported A$19.7M of cash at June 2022 from the quarterly report.
-
FY2024 cash of A$1.99M includes A$2.61M of share subscription money received in advance and held in trust. Underlying cash at bank was a A$0.62M overdraft.
-
FY2026 cash is A$1.20M in the balance sheet; A$1.27M including cash in assets held for sale. Assets held for sale were A$0.61M; liabilities held for sale A$0.14M (WOAG).
Cash flow
FY2024 equity issued includes A$7.60M of net share proceeds plus A$2.61M received in advance. The FY2025 net change shown is on a restated basis.
Ratios
All ratios are derived. ROIC, net debt/EBITDA and interest coverage are not meaningful: EBITDA and EBIT are negative and the company holds net cash. The cash conversion cycle is not meaningful given negative gross margins and the absence of steady-state working capital disclosure.
Commentary on trends, inflections and drivers
Phase 1 — consumer-led growth (FY2019–FY2023). Revenue grew in an unbroken run of quarterly increases (12 consecutive quarters to June 2022), reaching A$9.3M in FY2022 and A$11.46M in FY2023. Growth was driven by Dirty Clean Food's expansion across WA independent grocers, food service and online, and by oat milk launches. Unit economics were poor throughout. FY2023 gross margin was only 6.2% (A$0.71M gross profit on A$11.46M revenue), and selling expenses (A$2.49M) and employee costs (A$7.21M) produced a loss of A$14.66M. The company burned A$13.3M of free cash flow in FY2023 alone, taking cash from A$19.5M to A$5.9M. This was the decisive inflection that forced the strategic reset.
Phase 2 — pivot and acquisition (FY2024). The divestment of DCF to its own CEO for A$1.5M, payable over five years, crystallised a A$1.36M loss on sale. DCF contributed A$7.28M to the FY2024 loss. At the same time, WOA spent A$4.19M acquiring Prolupin's German assets out of insolvency and booked A$1.20M of fixed asset impairments. The balance sheet was weakest at this point: working capital was negative (-A$0.56M), the current ratio was 0.88x, and the bank account was in overdraft but for A$2.61M of subscription monies held in trust.
Phase 3 — scaling attempt at negative margins (FY2025). As a pure lupin business, revenue rose more than six-fold to A$0.47M but gross margin was deeply negative (gross loss of A$0.34M as reported). Two equity raisings (A$6.14M of shares issued, A$5.70M net cash) funded operating outflows of A$3.49M. The restated FY2025 figures show the German operation losing A$3.09M on about A$0.25M of revenue.
Phase 4 — retrenchment (FY2026). The FY2026 group loss fell 47% to A$3.64M. Continuing operations lost only A$0.73M, but that was because other income of A$2.60M included two years of R&D tax refunds (A$2.26M) and A$0.29M of grant income from the Department of Energy & Economics. Underlying continuing cash burn before grants was about A$3.4M (operating outflow of A$0.89M plus A$2.55M of grants received). Management attributed the German losses to rising energy and labour costs, a fixed-cost base and low established capacity. The decision on 2 July 2026 to wind down Germany removes the largest source of losses but also nearly all revenue. Cash of A$1.27M at 30 June 2026 represented about 2.1 quarters of funding (Food & Drink Business, June 2026 quarterly). Management's response includes deferring part of board and executive fees and limiting near-term marketing and R&D spend.
Equity erosion: Cumulative issued capital of A$60.7M has been offset by accumulated losses of A$58.1M. Shareholders' equity of A$2.86M equals about 0.43 cents of NTA per share.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Reported Segments by Period
| Period | Reported segments | Notes |
|---|---|---|
FY2019–FY2023 | Effectively one operating business (Dirty Clean Food), with plant protein development as an emerging activity | In FY2022 Dirty Clean Food accounted for essentially all revenue (SmallCaps) |
FY2024 | Plant protein operations; Dirty Clean Food business | Segment naming per Pearler/Morningstar-derived description. DCF was discontinued on 23 April 2024 |
FY2025 (as originally reported) | Single lupin protein business (Australia corporate/R&D plus German manufacturing) | No associates or JVs |
FY2026 (and FY2025 restated) | Continuing operations (Australian parent: commercial, R&D, corporate) and Discontinued operations (Wide Open Agriculture Germany GmbH) | WOAG placed into administration; FY2025 restated |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Dirty Clean Food (discontinued Apr 2024) (AUD Mn, derived) | 11.46 | 8.92 | 0 | 0 |
Plant protein, continuing (Australian parent) (AUD Mn) | 0 | 0.07 | 0.22 | 0.12 |
Plant protein, Germany (WOAG, discontinued 2026) (AUD Mn, derived) | 0 | — | 0.25 | 0.70 |
Total group revenue incl. discontinued (AUD Mn) | 11.46 | 8.99 | 0.47 | 0.83 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment result | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Continuing operations loss after tax (AUD Mn) | -5.46 | -3.80 | -0.73 |
Discontinued operations loss after tax (AUD Mn) | -7.28 | -3.09 | -2.91 |
Group loss after tax (AUD Mn) | -12.74 | -6.89 | -3.64 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Continuing gross margin (%) | -244 | -353 |
Continuing revenue share of group (%) | 47 | 15 |
Germany revenue share of group (%) | 53 | 85 |
Group revenue YoY growth (%) | -95 | 76 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue, as originally reported (AUD Mn) | 9.30 | 11.46 | 8.99 | 0.47 | 0.83 |
Revenue, continuing ops latest basis (AUD Mn) | — | — | 0.07 | 0.22 | 0.12 |
Gross profit, as reported (AUD Mn) | — | 0.71 | 0.70 | -0.34 | — |
Gross profit, continuing ops restated (AUD Mn) | — | — | — | -0.53 | -0.44 |
Other income (AUD Mn) | — | 0.77 | 3.38 | 1.63 | 2.60 |
Operating income before finance costs, derived (AUD Mn) | — | -14.61 | -12.57 | -3.71 | -0.72 |
EBITDA, derived (AUD Mn) | -10.10 | -13.86 | -11.57 | -3.18 | -0.17 |
Pre-tax income (AUD Mn) | -10.80 | -14.66 | -12.74 | -6.89 | -3.64 |
Income tax expense (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net income, group (AUD Mn) | -10.80 | -14.66 | -12.74 | -6.89 | -3.64 |
Net income, continuing ops (AUD Mn) | — | -14.66 | -5.46 | -3.80 | -0.73 |
Basic EPS, group (A cents) | — | -10.27 | -7.40 | -1.29 | -0.56 |
Diluted EPS, group (A cents) | — | -10.27 | -7.40 | -1.29 | -0.56 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth, as reported (%) | 115 | 23 | -21 | -95 | 76 |
Gross margin, as reported (%) | — | 6.2 | 7.8 | -72.1 | — |
Gross margin, continuing ops (%) | — | — | — | -244.1 | -352.8 |
EBITDA margin (%) | -108.6 | -121.0 | -128.7 | -1,448.6 | -137.1 |
Net margin, group (%) | -116.1 | -128.0 | -141.7 | -1,469.6 | -440.8 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | 15.40 | 10.22 | 8.58 | 3.34 |
Cash and equivalents (AUD Mn) | 19.47 | 5.87 | 1.99 | 3.39 | 1.20 |
Short-term borrowings (AUD Mn) | — | 0.11 | 0.50 | 0.02 | 0 |
Long-term borrowings (AUD Mn) | — | 0.59 | 0 | 0 | 0 |
Lease liabilities, total (AUD Mn) | — | 2.01 | 0.54 | 0.82 | 0.01 |
Total debt incl. leases (AUD Mn) | — | 2.71 | 1.04 | 0.85 | 0.01 |
Net debt, negative = net cash (AUD Mn) | — | -3.16 | -0.95 | -2.54 | -1.19 |
Total equity (AUD Mn) | 23.98 | 10.11 | 5.20 | 6.28 | 2.86 |
Goodwill and intangibles (AUD Mn) | — | 0 | 1.21 | 0.16 | 0.03 |
Property, plant and equipment (AUD Mn) | — | 3.81 | 4.22 | 2.61 | 0.12 |
Current assets (AUD Mn) | — | 9.33 | 4.00 | 3.89 | 2.54 |
Current liabilities (AUD Mn) | — | 3.13 | 4.56 | 1.74 | 0.45 |
Working capital, derived (AUD Mn) | — | 6.20 | -0.56 | 2.15 | 2.09 |
Issued capital (AUD Mn) | 44.38 | 44.63 | 52.23 | 60.51 | 60.70 |
Accumulated losses (AUD Mn) | -24.48 | -39.14 | -51.88 | -56.02 | -58.11 |
NTA per share (A cents) | — | 7.06 | 4.57 | 0.92 | 0.43 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | -11.87 | -9.25 | -3.49 | -2.15 |
of which grants / R&D refunds received (AUD Mn) | — | 0.41 | 2.78 | 1.34 | 2.55 |
Capex (AUD Mn) | — | -1.44 | -0.58 | -0.01 | -0.01 |
Free cash flow, derived (AUD Mn) | — | -13.31 | -9.83 | -3.50 | -2.17 |
Acquisitions (AUD Mn) | — | 0 | -4.19 | 0 | 0 |
Proceeds from sale of business (AUD Mn) | — | 0 | 0.15 | 0 | 0 |
Equity issued, net (AUD Mn) | — | 0.16 | 10.21 | 5.70 | 0.20 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD Mn) | — | -13.62 | -3.64 | 0.93 | -2.12 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE, on average equity (%) | -86 | -166 | -120 | -80 |
ROA, on average assets (%) | -95 | -99 | -73 | -61 |
Current ratio (x) | 2.98 | 0.88 | 2.24 | 5.70 |
Debt to equity, incl. leases (x) | 0.27 | 0.20 | 0.13 | 0.003 |
Asset turnover (x) | 0.74 | 0.70 | 0.05 | 0.14 |
Revenue by Region
| Region (entity-based proxy) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia (AUD Mn) | 11.46 | 8.99 | 0.22 | 0.12 |
Europe / Germany (AUD Mn) | 0 | — | 0.25 | 0.70 |
Total (AUD Mn) | 11.46 | 8.99 | 0.47 | 0.83 |
Region Margins & Growth (%)
| Region (proxy) | FY2025 | FY2026 |
|---|---|---|
Australia growth (%) | -98 | -43 |
Europe / Germany growth (%) | — | 181 |
Country / Region Details
| Country / region | Activity disclosed | Period |
|---|---|---|
Australia | Corporate HQ, R&D, Curtin licence, proposed 10,000 tpa facility; product launches in FY2025 | Ongoing |
Germany / EU | Grimmen plant (2024–2026); first lupin oil sale to a European cosmetics firm; lupin protein launches in Europe in FY2025 | Wound down from Jul 2026 |
China | Univar Solutions China commercial rollout (beverage and nutrition), constrained by supply cost; CIIE participation | FY2026 |
South America | Product launches during FY2025 (customers not named) | FY2025 |
United States | — | FY2024–FY2025 |
India | Proeon Foods: conditional exclusive distribution rights; Shree Ram Agro / OMN9 framework | Aug–Sep 2026 |
Vietnam | Vietnam LifeScience Company framework, including a conditional five-year exclusive manufacturing clause | Sep 2026 |
Indonesia | PT Haldin Pacific Semesta framework | Sep 2026 |
Taiwan | DKSH Taiwan oat milk distribution (DCF era) | 2022–2024 |
Capital Markets
| Measure | Value | Source |
|---|---|---|
Recent trading range (Mar–Aug 2026) | A$0.007 – A$0.016 | ASX announcement price records (InvestSMART) |
52-week range (as of May 2026) | About A$0.01 – A$0.03 | Halo Technologies |
1-year performance vs ASX 200 | -55.2% relative | Market Index |
Performance since IPO (as of Aug 2025) | About -92% | Stoxray |
Frankfurt (2WO) | €0.0015 (26 Jun 2026); 52-week range €0.0015 – €0.0135 | StockAnalysis |
Share Price
| Metric | Jul 2025 | Mar 2026 | May 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|
Share price (AUD) | 0.016 | 0.016 | 0.012 | 0.009 | 0.010 |
Valuation Multiples
| Multiple | WOA |
|---|---|
Market capitalisation (AUD Mn) | 5.9 |
Enterprise value (AUD Mn) | about 4.6 (market cap less A$1.27M cash) |
EV / Sales FY2026 (x) | about 5.6 |
P/E | Not meaningful (losses) |
EV / EBITDA | Not meaningful (negative EBITDA) |
P/B (x) | about 2.1 (equity A$2.86M) |
Price / NTA (x) | about 2.1 (NTA 0.43c) |
Capital Markets — Analyst consensus
| Item | Detail |
|---|---|
Analyst consensus | None. Not covered by major brokers (Market Index) |
Dividend history | No dividends ever paid; none proposed for FY2026 |
Dividend policy | No dividends while loss-making |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | No borrowings at 30 June 2026; lease liabilities of A$9,250 (current) |
Listed options | WOAO |
Capital raising history (recent) | FY2024: A$7.60M net plus A$2.61M in advance; FY2025: A$6.14M of shares issued (A$5.70M net cash); FY2026: A$0.23M of shares issued |
Analyst Conclusions
Management guidance
Management has given no quantitative financial guidance. Stated FY2027 priorities are to complete the orderly German wind-down, establish contract manufacturing to re-supply existing customers, convert pipeline activity into sales, and develop protein, fibre and oil under the whole-of-seed model. Capital will be tied to demand, near-term marketing and R&D will be limited, and some fees and salaries will be deferred (FY2026 Appendix 4E). Operational targets are about 500–1,000 tpa via CMOs and a definitive CMO agreement within calendar 2026. For the long-term WA facility, the DFS is planned for 2027, FID for mid-2028 and first production no earlier than 2031.
Consensus expectations
There is no consensus, as no analysts cover the stock.
Bull case
-
Capital-light reset unlocks unit economics. Exiting Germany removes the business that lost A$2.91M in FY2026 (and A$3.09M in FY2025). If an Asian CMO can make isolate at a positive gross margin, the 8 customers and more than 30 launches already secured provide a ready base for revenue.
-
Whole-seed margin stacking. Oil (hypoallergenic, cosmetic-grade) and fibre raise value per tonne. The industrial study shows that co-products would exceed protein by volume (about 17,500 t of fibre against 10,000 t of isolate).
-
Asymmetric valuation. At an enterprise value of about A$4.6M, the market ascribes little value to an exclusive global IP platform with improved royalty terms, four CMO frameworks, and Univar (China) and Proeon (India) distribution pathways.
Bear case
-
Funding cliff. Cash of A$1.27M against about 2.1 quarters of funding means further dilutive raises are near-certain, at prices around one cent per share.
-
Track record of value destruction. DCF (A$11.5M revenue in FY2023 at a 6% gross margin) was sold for A$1.5M on deferred terms. The Prolupin plant (A$4.19M) was closed about two years after completion. Accumulated losses of A$58.1M nearly equal the A$60.7M of capital raised.
-
No manufacturing, no revenue. All four CMO agreements are non-binding. Continuing revenue was only A$0.12M in FY2026, customer supply has lapsed, and the A$311M industrial plant is unfunded and at least five years away.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| September 2026 quarterly (Appendix 4C) | By end Oct 2026 | Cash balance, burn rate and German wind-down costs |
| FY2026 audited Annual Report / auditor's going-concern opinion | Sep–Oct 2026 | Confirms unaudited figures; going-concern emphasis |
| 2026 AGM | Likely Nov 2026 | Board re-election, capital authority (e.g. Listing Rule 7.1A placement capacity) |
| Definitive CMO agreement | Targeted within calendar 2026 | Core to re-establishing supply |
| Capital raising | Likely within 1–2 quarters | Size, price and investor quality |
| First CMO-produced lupin isolate and customer re-supply | 2,027 | Validates the new model |
| Outcome of WOAG administration, including ownership of Prolupin patents and Luve trademark | 2026–2027 | IP perimeter and residual liabilities |
| Univar China volume restart | 2,027 | Largest named commercial channel |
| Lupin oil and fibre sales | 2026–2027 | Evidence for whole-seed economics |
| Collection of DCF deferred consideration | Ongoing | Related-party receivable |
| DFS funding decision for WA facility | 2,027 | Long-term option value |
Analyst verdict
Wide Open Agriculture is no longer the regenerative food company its name implies. After three strategic resets in four years, it has become a lupin ingredient IP company with almost no operating footprint. The FY2026 numbers show both the logic and the weakness of the reset. The group loss fell 47% to A$3.64M and the balance sheet is debt-free. But continuing revenue was just A$0.12M, the improvement leaned on A$2.26M of two-year R&D refunds, and cash of A$1.27M covers only about two quarters.
The investment case now depends on one question: can a third-party manufacturer in Asia produce WOA's lupin isolate at a cost that supports a positive gross margin? WOA's own attempts at the Perth pilot plant and the Grimmen facility did not. Since July 2026 the new leadership team, led by a CEO with credible B2B ingredient experience, has moved quickly. It renegotiated the Curtin royalty, signed four IP-protective framework agreements across three countries, produced evidence for oil and fibre co-products, and published an industrial-scale study. These are sensible steps, but none is yet binding or revenue-generating.
The stock trades at roughly 2x NTA and about 5–6x trailing sales. That valuation reflects option value on the IP platform rather than any underlying earnings. Near-term dilution looks unavoidable, and the history of capital destruction (A$58M of accumulated losses) argues for scepticism until a definitive CMO contract and first re-supply orders are announced.
**Overall assessment: speculative / high-risk. The key downgrade trigger would be a qualified going-concern opinion combined with any delay to the CMO timetable beyond early 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background |
|---|---|---|---|
Craig Swan | Chief Executive Officer | Since 7 Apr 2026 | More than 30 years in B2B food ingredients, including senior roles at Goodman Fielder Ingredients, NutraSweet and Givaudan (ASX announcement, 3 Mar 2026) |
CFO / Company Secretary | — | — | Not identified in sources reviewed. |
Board of Directors
| Name | Role | Appointed | Background | Independence | Disclosed holding (Market Index) |
|---|---|---|---|---|---|
Justin Brown | Non-Executive Chair | May 2026 | The company cites significant capital markets experience and a record of developing and executing growth strategies at ASX-listed companies | Not formally disclosed in sources reviewed | 1,760,994 shares; 3,869,565 options (4 May 2026) |
Matthew Skinner | Non-Executive Director | NED since Mar 2026 | CFO from FY2023; interim CEO from Mar 2024; CEO until Apr 2026 | Not independent (former executive within three years) | 854,768 shares; 2,475,440 options (3 Mar 2026) |
Vincent Lauwerier | Non-Executive Director | Dec 2025 quarter | Not detailed in sources reviewed | — | — |
Jack Guidry | Non-Executive Director | FY2026 (holding notice dated 4 May 2026) | Not detailed in sources reviewed | — | 400,000 shares (4 May 2026) |
“—” = not publicly disclosed.
Board of Directors — Yaxi Zhan
| Name | Former role | Departure | Context |
|---|---|---|---|
Yaxi Zhan | Chair | May 2026 | Replaced by Justin Brown in the board renewal |
Anthony Maslin | Founding director (former Chair) | May 2026 | Co-founder; exit from the board ends founder representation |
Claudia Kwan | Non-Executive Director | Mar 2026 (appointed Sep 2025 quarter) | Stepped down for personal and professional reasons; remains a strategic adviser on investor and partnership opportunities |
Executive Leadership Team — Dr Ben Cole
| Name | Role | Period |
|---|---|---|
Dr Ben Cole | Co-founder; Managing Director | 2015 – c. Holds about 5.9M shares (0.90%) plus 5.0M (Market Index) |
Anthony Maslin | Co-founder; Founding Chair, later director | 2015 – May 2026 |
Stuart McAlpine | Non-Executive Director | Early years (described as former director by 2022) |
Jay Albany | CEO, Dirty Clean Food, then Group CEO | Group CEO Dec 2022 – Mar 2024 (left to buy DCF) |
Matthew Skinner | CFO, then interim CEO, then CEO | FY2023 – Apr 2026 |
Major Shareholders
| Holder type | Detail |
|---|---|
Institutional ownership | Not publicly disclosed; no substantial institutional holders identified |
Insider ownership (identified) | Justin Brown 1.76M shares; Matthew Skinner 0.85M; Jack Guidry 0.40M; Ben Cole (founder, not a director) about 10.9M across two holdings. Identified insiders hold roughly 2% of about 654M shares (derived) |
Competitive Landscape
Key Competitors
| Competitor | Segment | Relationship to WOA | Scale (approximate) | Positioning |
|---|---|---|---|---|
Roquette (France, private) | Pea protein isolates | Direct substitute in plant-based dairy, meat and nutrition | Multi-billion-euro revenue | Global leader in pea protein; scale cost advantage |
Cargill (US, private; including PURIS partnership) | Pea and other plant proteins | Substitute | Over US$100B group revenue | Integrated supply chain; global customer access |
ADM (NYSE: ADM) | Soy, pea and specialty proteins | Substitute | Tens of billions of US$ | Broad portfolio and flavour systems |
Ingredion (NYSE: INGR) | Pulse proteins (pea, faba) | Substitute | Multi-billion US$ | Texturiser and protein solutions |
Cosucra (Belgium, private) | Pea protein, chicory fibre | Substitute (protein and fibre) | Mid-size | European pulse specialist; competes on fibre too |
Burcon NutraScience (TSX: BU) | Pea, canola and other novel isolates | Closest listed analogue (IP-led plant protein developer) | Small | Process IP and partner-manufacturing model, similar to WOA's new model |
Australian Plant Proteins (private, Victoria) | Faba/pulse protein isolates | Australian regional competitor | Small | Domestic pulse isolate capacity |
Soy protein producers (various) | Soy isolates | Commodity benchmark | Very large | Lowest-cost incumbent protein |
Australian lupin flake and flour processors (e.g. Coorow Seeds) | Lupin flour and flakes | Competes for food-grade lupin demand | Small | Lower-processed lupin foods |
Former Prolupin brand ecosystem (Germany) | Lupin isolate | Acquired by WOA; EU lupin start-ups continue to emerge | Small | WOA's German exit leaves an opening for other EU lupin processors |
Proeon Foods (as a competitor) | Mung bean and peanut isolates | Now a framework partner; competes in plant protein generally | Small | Note potential conflict, mitigated by IP clauses |
Peer Comparison FY2026
| Metric | WOA FY2026 | Large pulse protein majors |
|---|---|---|
Revenue | 0.83 | Billions |
Revenue growth | +76% (group, mixed basis) | Low single digits typical |
Gross margin | Negative (-353% continuing) | Positive |



